Global Carcinoembryonic
Antigen market is expected to reach USD
2.56 Billion by 2022, according to a new study by Grand View Research, Inc.
Constant technological advancements pertaining to the development of novel
biomarkers which can be used in combination with other biomarkers is expected
to boost usage rates over the forecast period.
According
to the WHO estimates in 2012, global cancer incidences were nearly 14.1
million, which include 6.7 million female patients and 7.4 million male
patients. Increasing demand for minimally invasive diagnostics procedures is
also expected to play a vital role in determining market growth. Key advantages
associated with minimally invasive diagnostics procedures include elevated
patient satisfaction levels as they entail minor incision wounds. In addition,
these procedures involve relatively lesser hospital stays and therefore, are
economically viable and involve fewer post procedure complications.
Carcinoembryonic antigen market, by
application, 2012 – 2022 (USD Million)
View summary of this report @ http://www.grandviewresearch.com/industry-analysis/carcinoembryonic-antigen-cea-market
Further
key findings from the study suggest:
Colorectal cancer was one of the largest revenue generating
application segment of the carcinoembryonic antigen market and was estimated at
USD 639.65 million in 2014. Increasing prevalence of colorectal cancer
and usage of carcinoembryonic antigen tests at various stages is one of the
critical factors accounting for its large share.For instance, in 2012, new
cases of colorectal cancer were estimated to be over 93,000 and death due to
colorectal cancer is expected to be over 49,700 in the U.S alone.
Carcinoembryonic
antigen based breast cancer diagnosis is identified as the most lucrative
application segment of the market. The market is driven by factors such as
growing number of female population above 50 years, growing demand for Hormone
Replacement Therapy (HRT) and cosmetic surgeries. Moreover, growing patient
awareness levels and the presence of favorable government initiatives are
expected to improve treatment rates over the forecast period.
North
America was the largest regional market in 2014 owing to, the presence of high
incidence rates, presence of favorable reimbursement framework, and high
consumer awareness levels coupled with relatively higher healthcare expenditure
levels.
Asia
Pacific is anticipated to witness the most lucrative growth over the forecast
period. The presence of untapped opportunities, constantly improving healthcare
infrastructure, economic development, and improving patient awareness levels
are some factors accounting for this rapid growth.
Key
players operating in carcinoembryonic antigen market include Abbott
Diagnostics, Quest Diagnostics, Roche Diagnostics, GenWay Biotech Inc. and Correlogic
Systems, Inc.
For
the purpose of this study, Grand View Research has segmented the
carcinoembryonic antigen market on the basis of application, and region:
Carcinoembryonic
Antigen Application Outlook (Revenue, USD Million, 2012 – 2022)
·
Colorectal
cancer
·
Pancreatic
cancer
·
Ovarian
cancer
·
Breast
cancer
·
Thyroid
cancer
·
Others
Carcinoembryonic
Antigen Regional Outlook (Revenue, USD Million, 2012 – 2022)
·
North
America
·
U.S.
·
Canada
·
Europe
·
Germany
·
France
·
Spain
·
Asia
Pacific
·
China
·
Japan
·
India
·
MEA
·
South
Africa
·
Latin
America
·
Brazil
·
Mexico
Request
for free sample of this report @ http://www.grandviewresearch.com/industry-analysis/carcinoembryonic-antigen-cea-market/request
About
Grand View Research
Grand View Research, Inc. is a market research and consulting
company that provides off-the-shelf, customized research reports and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and energy. With a
deep-seated understanding of varied business environments, Grand View Research
provides strategic objective insights.
Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:
sales@grandviewresearch.com
Website: Grand
View Research
No comments:
Post a Comment